Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Article Life Sciences & Pharma AI and Biopharma: New Solutions Emerging Across the US Value Chain December 6, 2024
Video / Webinar Healthcare Services AI in Healthcare: Passive, Reactive, or Proactive? August 2, 2024
Published Articles Marketing & Sales Understanding the ‘Cookie Apocalypse’ and Its Impact on Online Advertising February 23, 2024
Article Mental and Behavioral Health Exploring the Psychedelics Landscape: Looking Ahead to Funding in 2024 February 20, 2024